We characterized the association between tumor size kinetics and survival in patients with
advanced urothelial carcinoma treated with atezolizumab (anti‐programmed death‐ligand 1 …

Objectives Recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma
(HNSCC) is currently an incurable disease. To improve treatment strategies, combinations of …

We translated two cancer vaccine strategies from mice into human clinical trials.(1) In
preclinical studies on TARP, an antigen expressed in most prostate cancers, we mapped …

Purpose: We applied a method that analyzes tumor response, quantifying the rates of tumor
growth (g) and regression (d), using tumor measurements obtained while patients receive …

Targeted therapies, immunotherapies, and improved chemotherapies are being developed
to reduce the suffering and mortality that come from human cancer. Although these …

Achieving systemic tumor control across metastases is vital for long-term patient survival but
remains intractable in many patients. High lesion-level response heterogeneity persists …

Sipuleucel-T is an autologous cellular immunotherapy used to treat asymptomatic or
minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Traditional …

Client-owned pet dogs represent exceptional translational models for advancement of
cancer research because they reflect the complex heterogeneity observed in human cancer …

Model‐informed drug development (MIDD) approaches have rapidly advanced in drug
development in recent years. Additionally, the Prescription Drug User Fee Act (PDUFA) VI …

Background Significant progress in treatment of metastatic castration resistant prostate
cancer (mCRPC) has been made. Biomarkers to tailor therapy are scarce. To facilitate …